#Prenatal and Newborn Genetic Testing Market Research | Explore Tumblr posts and blogs

datalyst · 3 months ago

Text

The Molecular Diagnostics Market: A Deep Dive into Precision Medicine and Technological Advancements

The Molecular Diagnostics Market has emerged as a critical player, driving advancements in precision medicine. This sector's ability to provide specific, reliable, and real-time data at the molecular level has accelerated the development of personalized treatments, enabling clinicians to diagnose diseases earlier and more accurately. From its foundation in genomics to its expanding applications across oncology, infectious diseases, and genetic testing, the molecular diagnostics market is witnessing rapid growth. This blog will explore the molecular diagnostics landscape, its primary technologies, industry growth drivers, and key challenges.

Understanding Molecular Diagnostics

Molecular diagnostics is a field that focuses on analyzing biological markers in the genome and proteome—the individual’s genetic code and how cells express their genes. These diagnostics provide insights into the molecular underpinnings of disease, often involving DNA or RNA detection to understand the health status or predisposition to specific conditions. Unlike traditional diagnostics, molecular diagnostics reveals the root cause at the molecular level, allowing for precise interventions tailored to the patient.

Major Segments in Molecular Diagnostics

The molecular diagnostics market encompasses several segments based on technologies, applications, end-users, and regions.

Technology Key technologies in molecular diagnostics include Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), DNA Microarrays, and In Situ Hybridization (ISH). PCR remains a staple in molecular testing for its simplicity and efficiency, while NGS has unlocked unprecedented possibilities in genomic testing. DNA microarrays, once the go-to technology, continue to play a role in specialized applications, particularly when high-throughput screening is necessary.

Application Applications in molecular diagnostics are vast, with significant focus areas in oncology, infectious disease testing, genetic testing, and pharmacogenomics. Oncology has been one of the fastest-growing applications, given the increasing prevalence of cancers worldwide. In infectious disease testing, molecular diagnostics was instrumental in managing the COVID-19 pandemic, bringing global attention to its capabilities. Genetic testing, which includes prenatal testing and newborn screening, is another vital segment, especially as it enables early disease detection and the potential for preventive care.

End-Users Molecular diagnostics primarily serves hospitals, diagnostic laboratories, academic and research institutes, and even home healthcare setups. Hospitals and diagnostic laboratories account for the highest share due to the need for advanced equipment, high-volume testing, and expert personnel.

The Growth Dynamics of the Molecular Diagnostics Market

The global molecular diagnostics market is projected to grow significantly in the coming years, driven by various factors:

Rising Incidences of Chronic and Infectious Diseases Chronic diseases like cancer, cardiovascular diseases, and diabetes are on the rise globally. Molecular diagnostics enables earlier and more accurate diagnosis, facilitating timely and targeted treatment. Similarly, infectious diseases—such as HIV, hepatitis, tuberculosis, and, more recently, COVID-19—require rapid diagnosis, which molecular diagnostics can deliver with high precision.

Expansion of Precision Medicine Precision medicine, which focuses on tailoring treatment to the individual, has been a major growth driver. Molecular diagnostics enables the identification of patient-specific mutations and disease markers, leading to personalized treatment plans that improve outcomes. The ability to select targeted therapies is particularly significant in cancer treatment, where one-size-fits-all approaches often fall short.

Technological Advancements The molecular diagnostics market has benefited tremendously from technological advancements. The introduction of digital PCR, automated and high-throughput NGS platforms, and enhanced bioinformatics tools has increased testing speed, accuracy, and affordability. Additionally, advancements in artificial intelligence (AI) and machine learning are enabling better data analysis, predictive modeling, and decision-making.

Growing Demand for Point-of-Care Diagnostics Point-of-care (POC) diagnostics allow for on-the-spot testing, often in non-laboratory environments, which can be particularly valuable in managing diseases in remote or underserved areas. As molecular diagnostics advances in miniaturization and automation, point-of-care molecular tests are becoming increasingly feasible, allowing for broader deployment.

Key Technologies Shaping Molecular Diagnostics

Polymerase Chain Reaction (PCR) PCR is a cornerstone of molecular diagnostics, offering simplicity, rapidity, and affordability. Real-time PCR (qPCR) and reverse-transcriptase PCR (RT-PCR) have been widely used, especially in infectious disease testing. The COVID-19 pandemic highlighted PCR's importance, demonstrating its ability to provide accurate and rapid results.

Next-Generation Sequencing (NGS) NGS enables comprehensive genetic analysis, allowing for the simultaneous sequencing of millions of DNA strands. NGS is pivotal in oncology, where it identifies specific mutations associated with cancers. In infectious disease control, NGS helps trace pathogens and track mutations, proving invaluable in managing outbreaks.

CRISPR-based Diagnostics Though still emerging, CRISPR technology is beginning to influence the molecular diagnostics space, especially in infectious disease detection. CRISPR diagnostics leverages gene-editing technology to identify specific DNA or RNA sequences, offering a high level of precision. CRISPR diagnostics are fast, cost-effective, and highly specific, showing promise in point-of-care settings.

Digital PCR Digital PCR has taken PCR a step further by providing higher accuracy and sensitivity, making it ideal for detecting low-abundance DNA or RNA targets. Digital PCR is particularly useful in cancer mutation testing, where detecting rare mutations or quantifying gene expression levels is necessary.

The Role of Bioinformatics in Molecular Diagnostics

As molecular diagnostics involves analyzing large and complex datasets, bioinformatics has become indispensable. Advanced bioinformatics tools enable faster and more accurate analysis of NGS data, aiding in identifying disease markers, understanding drug resistance mechanisms, and providing clinical decision support. With the integration of AI, bioinformatics tools are evolving to predict disease outcomes, identify patient responses to treatment, and suggest targeted therapies, marking a shift toward predictive diagnostics.

Regional Insights: Global Reach of Molecular Diagnostics

The molecular diagnostics market has established a global presence, with key regions contributing uniquely:

North America is the largest market due to high healthcare spending, advanced infrastructure, and early adoption of cutting-edge technologies.

Europe is significant, driven by high incidences of chronic diseases and government support for molecular diagnostics in preventive care.

Asia-Pacific is the fastest-growing region due to rising healthcare awareness, improving infrastructure, and increasing incidences of infectious diseases. China and India are leading this growth, with a particular focus on infectious disease testing.

Latin America and the Middle East & Africa are also developing markets, with gradual adoption of molecular diagnostics.

Challenges and Future Prospects

Despite its growth, the molecular diagnostics market faces challenges, including:

High Costs The initial setup and ongoing operational costs for molecular diagnostics can be prohibitive, particularly in low-resource settings. Although prices have gradually decreased, high-end equipment like NGS systems remains costly.

Regulatory Hurdles Regulatory approval for molecular diagnostics is rigorous, ensuring safety and efficacy. However, the process can be lengthy, especially for innovative technologies like CRISPR and digital PCR.

Skilled Personnel Shortage Running molecular diagnostic tests often requires skilled personnel, limiting the technology's reach in rural and remote areas. Automated and point-of-care devices are gradually addressing this gap, but more workforce training is necessary.

The Road Ahead for Molecular Diagnostics

The future of molecular diagnostics looks promising, with an increasing shift toward preventive and personalized medicine. The integration of digital health tools, AI, and wearable diagnostics is set to enhance the speed and accessibility of molecular testing. Additionally, as sequencing technology becomes more cost-effective, its adoption in routine diagnostics will likely increase, bringing precision medicine to a broader population.

Pharmaceutical and biotech companies are also investing heavily in molecular diagnostics research, especially in companion diagnostics that guide drug development. This partnership between diagnostics and therapeutics will likely yield personalized, effective treatments that reduce side effects and improve patient outcomes.

Conclusion

The molecular diagnostics market is at the forefront of a healthcare transformation, spearheading a shift from reactive to proactive medicine. With its ability to diagnose diseases at the genetic level, tailor treatments to individual patients, and predict disease trajectories, molecular diagnostics is enabling a more personalized and effective healthcare system. The next decade promises even greater advancements, making molecular diagnostics an exciting field poised to redefine how we understand and treat disease.

0 notes

farmacuticals · 3 months ago

Text

Competitive Landscape and Key Players in SNP Genotyping Market

The SNP genotyping and analysis market is witnessing remarkable growth, driven by advancements in genomics and an increasing focus on personalized medicine. SNP (single nucleotide polymorphism) genotyping identifies variations in a single nucleotide in a genome, aiding in the study of genetic predispositions to various diseases, drug responses, and genetic traits. This market includes the technologies, tools, and services used to genotype SNPs and conduct analysis, which has widespread applications in research, diagnostics, and drug development. The demand for SNP genotyping and analysis is particularly high in the fields of oncology, pharmacogenomics, and agricultural research, as it enables deeper insights into genetic variations and their impact on individual and population-level health outcomes.

The SNP Genotyping and Analysis Market Size was projected to reach $13.7 billion (USD billion) in 2022 based on MRFR analysis. It is anticipated that the market for SNP genotyping and analysis will increase from 15.11 billion USD in 2023 to 36.6 billion USD in 2032. During the forecast period (2024-2032), the SNP Genotyping and Analysis Market is anticipated to develop at a CAGR of approximately 10.33%.

SNP Genotyping and Analysis Market Share

The SNP genotyping and analysis market share is primarily held by leading companies like Illumina, Thermo Fisher Scientific, and Bio-Rad Laboratories, which offer state-of-the-art genotyping tools, reagents, and software solutions. These companies dominate the market due to their advanced platforms, broad research capabilities, and established partnerships with research and clinical institutions. New market entrants, however, are gaining a foothold by focusing on cost-effective, high-throughput genotyping solutions. The market share is also geographically diverse, with North America and Europe holding prominent shares due to extensive research funding and a large base of biotech companies, while Asia-Pacific is rapidly growing due to expanding healthcare and research infrastructure.

SNP Genotyping and Analysis Market Analysis

SNP genotyping and analysis market analysis indicates significant growth potential due to the rising prevalence of chronic diseases and the increasing demand for genomic data in clinical and research settings. The analysis also shows that innovations in high-throughput sequencing and bioinformatics are facilitating more efficient, cost-effective SNP genotyping. Technologies like microarray analysis and next-generation sequencing (NGS) are key drivers, providing rapid and accurate SNP data at a fraction of traditional costs. This market analysis highlights the impact of growing awareness of genetic testing among patients and healthcare providers, as well as increasing investments by governments and private entities in genomic research. The focus on personalized medicine, where treatments are tailored to individual genetic profiles, is expected to drive continuous demand in the SNP genotyping and analysis market.

SNP Genotyping and Analysis Market Trends

Key SNP genotyping and analysis market trends include the adoption of automation and AI in genomics. AI-powered data analysis helps interpret large datasets generated by SNP genotyping, enabling faster and more accurate insights into genetic associations. Another trend is the increased use of SNP genotyping in non-invasive prenatal testing (NIPT) and newborn screening, which has become an essential aspect of early disease diagnosis and prevention. Furthermore, the integration of genotyping and bioinformatics platforms enables researchers to conduct more comprehensive analyses, streamlining the identification of disease-related SNPs. The growing interest in consumer genomics, where individuals can gain insights into their ancestry and health risks through direct-to-consumer (DTC) testing kits, is also impacting the SNP genotyping and analysis market.

Reasons to Buy the Reports

Market Insights and Forecasts: Detailed projections on the SNP genotyping and analysis market, including future opportunities and growth drivers.

Competitive Landscape: Comprehensive information on market share and strategic positioning of key players, enabling informed decision-making.

Technological Trends: Insights into the latest technological advancements, such as AI integration, next-generation sequencing, and bioinformatics tools in SNP genotyping.

Regional Analysis: Regional breakdowns and growth potential insights to help investors and companies identify high-opportunity areas globally.

Personalized Medicine Focus: Analysis of the expanding role of SNP genotyping in personalized medicine, highlighting its applications in oncology, pharmacogenomics, and genetic testing.

Recent Developments

Recent developments in the SNP genotyping and analysis market reflect a focus on expanding applications and improving technology. In 2023, Thermo Fisher Scientific launched a new NGS-based genotyping platform designed for high-accuracy pharmacogenomic research, enhancing its utility in personalized medicine. Illumina introduced a cost-effective array platform targeting SNP genotyping for agricultural genomics, providing a tailored solution for crop and livestock breeding. Additionally, Bio-Rad Laboratories announced a strategic collaboration to integrate its genotyping software with AI-powered bioinformatics tools, improving analysis speed and accuracy. Advancements in point-of-care (POC) genotyping devices have also been significant, allowing for rapid SNP analysis in clinical settings and contributing to the increased demand in the SNP genotyping and analysis market.

Related repots:

medical equipment rental market

medical radiation shielding market

membrane filtration market

oral solid dosage pharmaceutical market

0 notes

harshnews · 3 months ago

Text

Prenatal Genetic Counselling Market Size, Share, Trends, Growth and Competitive Outlook

"Prenatal Genetic Counselling Market – Industry Trends and Forecast to 2029

Global Prenatal Genetic Counselling Market, By Type (Predictive Testing, Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, Others), Technology (Cytogenetic Testing, Biochemical Testing, Molecular Testing), Application (Chromosome Analysis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, Others) – Industry Trends and Forecast to 2029

Access Full 350 Pages PDF Report @

**Segments**

- **Service Type**: The market can be segmented based on the type of services offered in prenatal genetic counseling such as screening services, diagnostic services, and genetic education services. - **End User**: Another segmentation criterion is based on the end users of prenatal genetic counseling services including hospitals, healthcare clinics, diagnostic centers, and research institutions. - **Mode of Consultation**: The market can also be analyzed by the mode of consultation i.e., whether it is conducted in-person or through teleconsultation services.

**Market Players**

- **Progenity, Inc.**: Progenity is a key player in the prenatal genetic counseling market, offering a range of services including carrier screening, non-invasive prenatal testing, and preimplantation genetic testing. - **Invitae Corporation**: Invitae offers comprehensive genetic testing services including prenatal genetic counseling, carrier screening, and diagnostic testing to healthcare providers and patients. - **Natera, Inc.**: Natera specializes in non-invasive prenatal testing and genetic screening services, providing accurate and reliable results to expectant parents and clinicians. - **PerkinElmer, Inc.**: PerkinElmer is a prominent player in the prenatal genetic counseling market, offering a wide array of genetic testing solutions for prenatal and postnatal care. - **Illumina, Inc.**: Illumina is known for its advanced sequencing and array technologies used in prenatal genetic counseling to assess genetic risks and provide personalized healthcare solutions.

The global prenatal genetic counseling market is witnessing significant growth due to the rising demand for personalized genetic testing services and increasing awareness about genetic disorders among expectant parents. The market segmentation based on service type, end user, and mode of consultation provides valuable insights for industry stakeholders to tailor their offerings and target specific customer segments efficiently. Key market players like Progenity, Inc., Invitae Corporation, Natera, Inc., PerkinElmer, Inc., and Illumina, Inc. are driving innovation and advancements in prenatalThe global prenatal genetic counseling market is experiencing substantial growth, driven by factors such as the increasing demand for personalized genetic testing services and the growing awareness about genetic disorders among expectant parents. The market segmentation based on service type, end user, and mode of consultation allows for a more targeted and efficient approach to meet the needs of specific customer segments within the industry.

The segmentation based on service type, which includes screening services, diagnostic services, and genetic education services, helps in understanding the different aspects of prenatal genetic counseling that are in demand within the market. Screening services are crucial for identifying potential genetic risks early on, while diagnostic services provide accurate assessments for expectant parents to make informed decisions. Genetic education services play a vital role in empowering individuals with knowledge about genetic disorders and their implications.

Another segmentation criterion is based on the end users of prenatal genetic counseling services, which include hospitals, healthcare clinics, diagnostic centers, and research institutions. Understanding the preferences and requirements of these different end users can help market players tailor their services and establish strong partnerships to reach a wider customer base.

Furthermore, the segmentation by the mode of consultation, whether in-person or through teleconsultation services, provides insights into the evolving trends in healthcare delivery. Teleconsultation services are gaining traction due to their convenience and accessibility, especially in remote areas where access to healthcare facilities may be limited. Incorporating teleconsultation services in prenatal genetic counseling can enhance outreach and improve patient engagement.

Key market players such as Progenity, Inc., Invitae Corporation, Natera, Inc., PerkinElmer, Inc., and Illumina, Inc. are at the forefront of driving innovation and advancements in prenatal genetic counseling. These companies offer a wide range of services, including carrier screening, non-invasive prenatal testing, preimplantation genetic testing, and comprehensive genetic testing solutions to cater to the diverse needs of healthcare providers and patients.

In conclusion, the global prenatal genetic counseling market is poised for continued growth and expansion, fueled by technological**Global Prenatal Genetic Counselling Market, By Type (Predictive Testing, Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, Others), Technology (Cytogenetic Testing, Biochemical Testing, Molecular Testing), Application (Chromosome Analysis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, Others) – Industry Trends and Forecast to 2029**

The global prenatal genetic counseling market is experiencing robust growth, driven by factors such as increasing demand for personalized genetic testing services and growing awareness about genetic disorders among expectant parents. Market segmentation based on service type, end user, and mode of consultation offers valuable insights for industry stakeholders to customize their offerings and efficiently target specific customer segments. Key players like Progenity, Invitae Corporation, Natera, PerkinElmer, and Illumina are leading innovation in prenatal genetic counseling, offering a wide array of services to cater to diverse needs.

The segmentation by service type, including predictive testing, carrier testing, prenatal and newborn testing, diagnostic testing, and pharmacogenomic testing, reflects the diverse requirements within the prenatal genetic counseling market. Predictive testing helps identify potential genetic risks, carrier testing assesses the likelihood of passing on genetic disorders, prenatal and newborn testing aid in early diagnosis, diagnostic testing provides accurate assessments, and pharmacogenomic testing personalizes healthcare based on genetic variations.

Technology segmentation, such as cytogenetic testing, biochemical testing, and molecular testing, highlights the different approaches used in genetic

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Prenatal Genetic Counselling Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Prenatal Genetic Counselling Market.

Global Prenatal Genetic Counselling Market survey report analyses the general market conditions such as product price, profit, capacity, production, supply, demand, and market growth rate which supports businesses on deciding upon several strategies. Furthermore, big sample sizes have been utilized for the data collection in this business report which suits the necessities of small, medium as well as large size of businesses. The report explains the moves of top market players and brands that range from developments, products launches, acquisitions, mergers, joint ventures, trending innovation and business policies.

The following are the regions covered in this report.

North America [U.S., Canada, Mexico]

Europe [Germany, UK, France, Italy, Rest of Europe]

Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]

South America [Brazil, Argentina, Rest of Latin America]

The Middle East & Africa [GCC, North Africa, South Africa, Rest of the Middle East and Africa]

This study answers to the below key questions:

What are the key factors driving the Prenatal Genetic Counselling Market?

What are the challenges to market growth?

Who are the key players in the Prenatal Genetic Counselling Market?

What are the market opportunities and threats faced by the key players?

Browse Trending Reports:

Asia Pacific Mainframe Market

Asia Pacific Menstrual Cramps Treatment Market

Europe Commercial Cleaning Equipment Market

Europe Mainframe Market

Europe Quantum Computing Market

Europe Tomatoes Market

Europe Utility Locator Market

India Blood Gas Analyzer Market

Middle East And Africa Commercial Cleaning Equipment Market

Middle East And Africa Neurosurgery Market

Middle East And Africa Sports Medicine Market

Middle East And Africa Vaccines Market

Nigeria Cassava Starch Market

Nigeria Starch Processing Market

North America Menstrual Cramps Treatment Market

North America Neurosurgery Market

West Africa Baby Food Market

Antenna Market

Baby Apparel Market

Cassava Starch Market

Castor Oil Market

Cenospheres Market

Coconut Water Market

Collagen Casings Market

Facility Management Market

Functional Confectionery Market

Hemp Seed Market

Infrared Imaging Market

Instant Noodles Market

Laundry Detergents Market

Menstrual Cramps Treatment Market

Micro And Nano Plc Market

Motorcycle Market

Neurosurgery Market

Nickel Alloy Market

Over The Counter Probiotic Supplements Market

Polycystic Kidney Disease Adpkd Market

Private Label Food And Beverage Market

Recreational Cannabis Market

Tofu And Tempeh Market

Tomatoes Market

Vaccines Market

Varnish Makers Market

Wireless Medical Device Connectivity Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: [email protected]"

#Prenatal Genetic Counselling Market

0 notes

market-insider · 5 months ago

Text

Preimplantation Genetic Testing Market Future Outlook: Analyzing Size, Share, and Growth Patterns

The global preimplantation genetic testing market size is expected to reach USD 1.54 billion by 2030, growing at 10.3% CAGR from 2024 to 2030, as per the new report by Grand View Research, Inc. Recent technological advancements in testing have changed the current practice of prenatal screening and early detection of chromosomal abnormalities in an embryo. Moreover, the introduction of novel technologies such as NGS, PCR, and FISH is expected to drive market growth over the forecast period.

Growing awareness about genetic diseases and novel techniques for the detection of chromosomal abnormalities and embryo screening for successful IVF holds growth prospects for this vertical over the forecast period. Key market players and service providers such as COOPER SURGICAL, INC. are running awareness campaigns to promote an increased understanding of the diseases and screening of these diseases at the early stages. Such favorable initiatives are expected to increase the demand for PDT in IVF procedures globally.

The increasing adoption of in vitro fertilization (IVF) technique consequently upsurges the utilization of preimplantation genetic testing (PGT). These techniques are advantageous in allowing the development of a healthy fetus and preventing the risk of selective pregnancy termination. Hence, PGT acts as an addendum to assisted reproductive technology.

Moreover, the increased risk of genetic disease in newborns and complications associated with IVF procedures push healthcare providers to recommend PGT. For instance, according to the CDC, in the U.S., about 6,000 babies are born with Down syndrome each year. It is the most common chromosomal condition diagnosed in newborns in the country. Moreover, the high risk associated with aged pregnancy further increases the adoption of PGT worldwide.

Key companies are involved in developing novel methods and solutions to carry out preimplantation genetic diagnosis and screening. To maintain their significant share in the revenue in the coming years, these participants are undertaking strategic initiatives. The strategic undertakings include regional expansion, collaborative development, and new product developments.

For instance, in October 2022, Ovation Fertility and Genomic Prediction partnered to expand genetic testing services by using the LifeView PGT platform for PFT. Moreover, in April 2022, Clevergene received PCPNDT for prenatal genetic testing. The company aimed to expand its services in preimplantation genetic screening and non-invasive prenatal testing.

For More Details or Sample Copy please visit link @: Preimplantation Genetic Testing Market Report

Preimplantation Genetic Testing Market Report Highlights

The rising incidence of genetic diseases has fueled the demand for preimplantation genetic testing (PGT). With increasing prevalence of genetic disorders, PGT has become crucial in IVF procedures.

The Polymerase Chain Reaction (PCR) segment dominated the preimplantation genetic testing market and contributed 39.8% to the market share in 2023.

The preimplantation genetic diagnosis segment dominated the preimplantation genetic testing market and contributed 77.0% of the market share in 2023.

Europe preimplantation genetic testing market dominated the global market in 2023, capturing the largest revenue share at 40.74%.

Gain deeper insights on the market and receive your free copy with TOC now @: Preimplantation Genetic Testing Market Report

Grand View Research has segmented the global Preimplantation Genetic Testing market on the basis of procedure, product, technology, application, end use, and region.

#PreimplantationGeneticTesting #PGT #GeneticScreening #IVF #ReproductiveHealth #GeneticTestingMarket #FertilityTreatment #EmbryoTesting #ReproductiveMedicine #HealthcareInnovation #PersonalizedMedicine #Genomics #FamilyPlanning #MedicalDiagnostics #HealthcareMarket

0 notes

healthcarehubhh · 7 months ago

Text

Genetic Testing Market is driven by advancements in Personalized Medicine

The global genetic testing market involves the analysis of human DNA, RNA, chromosomes or genes to detect alterations, mutations, deletions or duplications that indicate predisposition to certain genetic diseases or conditions. Genetic testing enables detection of gene variants linked to inherited conditions and plays an important role in the diagnosis and treatment of genetic disorders. Advancements in DNA sequencing technologies have increased the accessibility and clinical use of genetic testing. Whole genome sequencing and whole exome sequencing offer highly accurate and low-cost options for testing many genes at once. Genetic testing helps in disease risk assessment, carrier screening, prenatal testing, newborn screening and pharmacogenomic testing. Growing awareness about the benefits of genetic testing along with the rapidly declining costs have enabled healthcare providers to offer genomic screening to a larger patient population. The Global genetic testing market is estimated to be valued at US$ 18.24 Bn in 2024 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030. Key Takeaways Key players operating in the genetic testing market include 23&Me Inc., Qiagen NV, Eurofins Scientific, PerkinElmer Inc., Illumina Inc., Danaher Corporation, Myriad Genetics Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., Quest Diagnostics Incorporated, BioRad Laboratories Inc., and DiaSorin S.p.A. (Luminex Corporation), among others. 23&Me Inc. and AncestryDNA are leading direct-to-consumer genetic testing companies. The growing demand for personalized medicine is driving the adoption of genetic testing. Genetic testing plays a key role in tailoring medical management plans based on patients’ genetic makeup. It helps identify disease predispositions and select optimal treatments accordingly. Advancements in whole genome and whole exome sequencing technologies have expanded clinical applications of genetic testing. The genetic testing market is witnessing significant growth in emerging Asian and Latin American countries. Increasing healthcare expenditure, rising focus on genetic disease research and growing awareness about genomic medicine are fueling the global expansion of the genetic testing industry. Various startups are also offering direct-to-consumer genetic testing services in developing nations. Market Drivers The advancement in Next-Generation Sequencing (NGS) technologies is a major driver of the genetic testing market. NGS has enabled high-throughput, affordable sequencing of entire human genomes within a single day. This has facilitated mainstream clinical applications of genetic testing for conditions with known genetic causes. Growing research into pharmacogenomics is another key factor propelling the market growth. Pharmacogenomic testing helps determine individual genetic variations that influence drug responses and enables selection of most effective medications. Rising burden of chronic diseases along with increasing geriatric population susceptible to genetic disorders will also augment the demand for genetic testing in the coming years.

#Genetic Testing Market Analysis #Genetic Testing Market Size #Genetic Testing Market Demand.

0 notes

aimarketresearch · 11 months ago

Text

0 notes

priyanshisingh · 1 year ago

Text

Molecular Diagnostics Instruments Market Global industry share, growth, drivers, emerging technologies, and forecast research report 2030

The latest market report published by Credence Research, Inc. “Global Molecular Diagnostics Instruments Market: Growth, Future Prospects, and Competitive Analysis, 2022 – 2030. The global demand for molecular diagnostics instruments was valued at USD 15.9 Billion in 2022 and is expected to reach USD 34.4 Billion in 2030, growing at a CAGR of 11.7% between 2023 and 2030.

Molecular diagnostics instruments play a crucial role in the field of medical diagnostics by enabling the detection and analysis of genetic material, proteins, and other molecules associated with diseases. These instruments are used to identify specific genetic mutations, pathogens, and biomarkers, aiding in early disease detection, personalized medicine, and treatment monitoring.

Molecular Diagnostics Instruments Market Dynamics refer to the ever-evolving nature of the market for instruments used in molecular diagnostics. This field encompasses a wide range of technologies and techniques that analyze biological markers at the molecular level, enabling accurate diagnosis and monitoring of diseases. The dynamics within this market are driven by several factors, including technological advancements, increasing demand for personalized medicine, and growing awareness about early disease detection. With rapid developments in genomics and proteomics research, there has been a surge in the adoption of advanced diagnostic tools such as PCR machines, DNA sequencers, microarrays, and mass spectrometers. These instruments play a crucial role in identifying genetic mutations or alterations associated with various diseases like cancer or infectious pathogens.

Key Instruments and Platforms:

Polymerase Chain Reaction (PCR) Systems: PCR instruments amplify and analyze DNA or RNA segments, allowing for the detection of specific genetic sequences. Real-time PCR systems provide quantitative results and are widely used in various diagnostic applications.

Next-Generation Sequencing (NGS) Systems: NGS platforms analyze DNA or RNA sequences on a large scale, enabling the detection of genetic variations, mutations, and gene expression levels. NGS has revolutionized genomic analysis and personalized medicine.

Microarrays: DNA microarrays can analyze thousands of genes simultaneously, making them valuable for gene expression profiling, genotyping, and detection of genetic variants.

Mass Spectrometers: Mass spectrometry-based platforms analyze proteins and peptides, facilitating the identification of disease markers and the study of proteomics.

In-situ Hybridization Systems: These systems visualize the location of specific nucleic acid sequences within tissue samples, aiding in the diagnosis of diseases like cancer.

Digital PCR Systems: Digital PCR provides absolute quantification of nucleic acids, enhancing sensitivity and precision in detecting rare genetic mutations or pathogens.

Applications of Molecular Diagnostics Instruments:

Infectious Disease Diagnostics: Molecular diagnostics instruments are widely used to detect pathogens such as viruses, bacteria, and fungi. They play a critical role in diagnosing diseases like HIV, hepatitis, influenza, and COVID-19.

Cancer Diagnostics: Molecular testing helps identify genetic mutations and biomarkers associated with different types of cancer, guiding treatment decisions and monitoring patient response.

Genetic Testing: These instruments are used for carrier testing, prenatal testing, newborn screening, and genetic counseling to assess the risk of inherited disorders.

Pharmacogenomics: Molecular diagnostics aid in tailoring drug therapies based on an individual's genetic makeup, maximizing treatment effectiveness and minimizing adverse effects.

Key Players and Market Landscape:

The molecular diagnostics instruments market is characterized by a range of established companies and emerging players. Prominent manufacturers include Thermo Fisher Scientific, Roche Diagnostics, QIAGEN, Abbott Laboratories, Illumina, and Bio-Rad Laboratories.

Future Outlook:

The molecular diagnostics instruments market is expected to witness continued growth driven by technological advancements, increased adoption of precision medicine, and the ongoing need for accurate and rapid disease detection and monitoring.

Browse 235 pages report Molecular Diagnostics Instruments Market By Technology (Polymerase Chain Reaction (PCR), Hybridization, DNA sequencing, Microarray, Isothermal Nucleic Acid Amplification Technology (INAAT), Others) By Application (Infectious diseases, Oncology, Genetic testing, Blood screening) - Growth, Future Prospects & Competitive Analysis, 2016 – 2030)- https://www.credenceresearch.com/report/molecular-diagnostics-instruments-market

Molecular Diagnostics Instruments Market Recommendations:

Invest in Technology Advancements: Stay at the forefront of technological innovations by investing in research and development efforts that enhance the capabilities and efficiency of molecular diagnostics instruments. Embrace emerging technologies such as artificial intelligence, machine learning, and automation to streamline workflows, improve accuracy, and expedite data analysis.

Quality Assurance and Standardization: Prioritize rigorous quality control and validation processes to ensure the accuracy, reliability, and reproducibility of molecular diagnostic tests. Adherence to regulatory guidelines and industry standards is essential to maintain confidence in test results and promote patient safety.

Collaborate Across Disciplines: Foster interdisciplinary collaborations between molecular biologists, clinicians, bioinformaticians, and engineers to leverage diverse expertise for comprehensive diagnostic solutions. Collaborative efforts can lead to the development of integrated platforms that offer seamless sample processing, analysis, and interpretation.

Focus on User-Friendly Design: Design molecular diagnostics instruments with user-friendly interfaces, intuitive workflows, and clear data visualization to facilitate ease of use by laboratory professionals and clinicians. Intuitive instruments enhance efficiency, reduce errors, and increase adoption rates.

Educate and Train Personnel: Provide comprehensive training programs for laboratory personnel and healthcare professionals to ensure proficient operation of molecular diagnostics instruments and accurate interpretation of test results. Continuous education empowers users to harness the full potential of these technologies.

Data Integration and Interpretation: Develop robust bioinformatics tools and software solutions that enable efficient data integration, analysis, and interpretation. User-friendly interfaces and automated algorithms can assist in transforming complex molecular data into clinically actionable insights.

Adopt a Patient-Centric Approach: Prioritize patient needs and clinical relevance when designing assays and selecting molecular diagnostics instruments. Tailor diagnostic solutions to address specific healthcare challenges, improve disease detection, and guide personalized treatment decisions.

Global Access and Equity: Work towards ensuring global access to molecular diagnostics instruments, especially in resource-limited settings. Develop cost-effective solutions that can be deployed in diverse healthcare settings, contributing to equitable healthcare delivery.

Regulatory Compliance: Stay informed about evolving regulatory requirements and compliance standards for molecular diagnostics. Proactively engage with regulatory authorities to navigate the approval process and ensure the timely launch of validated assays and instruments.

Continuous Research and Validation: Encourage ongoing research and validation studies to demonstrate the clinical utility, cost-effectiveness, and patient outcomes associated with molecular diagnostics instruments. Collaborate with healthcare providers and researchers to generate robust evidence supporting the adoption of these technologies.

Why to Buy This Report-

The report provides a qualitative as well as quantitative analysis of the global Molecular Diagnostics Instruments Market by segments, current trends, drivers, restraints, opportunities, challenges, and market dynamics with the historical period from 2016-2020, the base year- 2021, and the projection period 2022-2028.

The report includes information on the competitive landscape, such as how the market's top competitors operate at the global, regional, and country levels.

Major nations in each region with their import/export statistics

The global Molecular Diagnostics Instruments Market report also includes the analysis of the market at a global, regional, and country-level along with key market trends, major players analysis, market growth strategies, and key application areas.

Browse Full Report: https://www.credenceresearch.com/report/molecular-diagnostics-instruments-market

Visit: https://www.credenceresearch.com/

Related Report: https://www.credenceresearch.com/report/poc-molecular-diagnostics-market

Related Report: https://www.credenceresearch.com/report/remote-patient-monitoring-devices-market

Browse Our Blog: https://www.linkedin.com/pulse/molecular-diagnostics-instruments-market-size-expected-singh

Browse Our Blog: https://medium.com/@priyanshi_97937/molecular-diagnostics-instruments-market-analysis-with-size-revenue-growth-drivers-and-forecast-3c1871e406ab

About Us -

Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 10,000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives. For nearly a century, we’ve built a company well-prepared for this task.

Office No 3 Second Floor, Abhilasha Bhawan, Pinto Park, Gwalior [M.P] 474005 India

0 notes

prabha194 · 2 years ago

Text

Prenatal and Newborn Genetic Testing Market Opportunity Assessment, Market Challenges, Key vendor analysis, Vendor landscape by 2027

According to The Insight Partners market research study titled “Prenatal and Newborn Genetic Testing Market - Global Analysis and Forecasts by Product, Disease Indication and End User”. The Global Prenatal and Newborn Genetic Testing Market is expected to reach US$ 11,204.7 Mn in 2027 from US$ 4,034.4 in 2018. The market is estimated to grow with a CAGR of 12.2% from 2019-2027. The report highlights the trends prevalent in the global prenatal and newborn genetic testing market and the factors driving the market along with those that act as deterrents to its growth.

The key factors that are driving the growth of the significant increase in the prevalence of genetic diseases among infants, supportive government for promoting the use of prenatal and newborn testing and increasing birth rate are boosting the market over the years. In addition, the growth opportunities in emerging markets in developing countries are likely to have a positive impact on the growth of the market in the coming years.

Request Copy of Prenatal and Newborn Genetic Testing Market Growth Report https://www.theinsightpartners.com/sample/TIPBT00002550/

Several types of genetic diseases affect the fetuses in the womb. The way in which these genetic diseases are inherited helps to determine the risk that they pose on pregnancy as well as the risk of its recurrence. The risk of having genetic diseases in babies is high in cases where the parents have another child with a genetic disease, family history of a genetic disorder, or if either of a parent has a chromosomal abnormality. There is a significant prevalence of genetic diseases among infants. Moreover, these diseases are also responsible for infant mortality across the globe. For instance, according to the World Health Organization 2016, an estimated 7.9 million infants across the world are born with genetic defects. Moreover, according to the Centers for Disease Control and Prevention (CDC), birth defects affects every 1 in 33 babies born in the US. On the other hand, chromosomal abnormalities such as Down syndrome affects 1 in 691 babies born in the US, as per the CDC’s data in 2017. Thus, the high prevalence of genetic diseases among infants account for the increasing demands for prenatal and newborn genetic tests, thereby contributing to the growth of the market.

Global Prenatal and Newborn Genetic Testing Market was segmented by product, disease indication, and end user. The product segment was further divided as diagnostic and screening. On the basis of disease indication, the market is segmented into the cystic fibrosis, sickle cell anemia, Down syndrome, phenylketonuria, and other diseases. Based on the end user, the prenatal and newborn genetic testing market is segmented into hospitals and clinics, diagnostic centers, other end users. The hospitals and clinics held a major market share among the end user segment as they are the primary healthcare centres for all patients.

Some of the major primary and secondary sources included in the report for the Prenatal and Newborn Genetic Testing Market are the World Health Organization, UAE Genetic Diseases Association, Centre for Arab Genomic Studies, National Health Service (NHS), Centers for Disease Control and Prevention, National Human Genome Research Institute (US), Florida Department of Health and others.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

#Prenatal and Newborn Genetic Testing Market #Prenatal and Newborn Genetic Testing Market Research #Prenatal and Newborn Genetic Testing Market Insight #Prenatal and Newborn Genetic Testing Market Trends #Prenatal and Newborn Genetic Testing Market Forecast

0 notes

themedicalstate · 4 years ago

Photo

23 and Baby

By Tanya Lewis (Scientific American). Image Credit: Enan Liang.

We now have the ability to screen for thousands of genetic diseases in newborns. That may not always be the healthy thing to do

Mitchell Gorby came into this world around 3 P.M. on August 9, 2019, at Balboa Naval Hospital in San Diego. The baby seemed healthy, and his parents, Tiffany and Rylan, were thrilled. But a few hours later a nurse noticed that Mitchell seemed lethargic and never cried, and monitors indicated that his body was not getting enough oxygen. Mitchell was rushed to the neonatal intensive care unit at nearby Rady Children’s Hospital, where tests revealed that oxygen wasn’t bonding to the molecule that carries it through the blood, hemoglobin, and his red blood cells were dying off. He wasn’t nursing, so the hospital put in a feeding tube. Mitchell’s doctor ordered CT and brain scans and tested for infectious diseases—but she could not figure out what was wrong with him. As a last resort, she suggested sequencing Mitchell’s genome.

The results from Stephen Kingsmore’s laboratory at the Rady Children’s Institute for Genomic Medicine came back within about 48 hours. Mitchell had a rare genetic mutation known as hemoglobin Toms River, which prevents oxygen from bonding to the proteins in fetal red blood cells. The mutation—named after the New Jersey hometown of the first patient identified with the problem in 2011—affects only fetal hemoglobin; babies start making healthy adult hemoglobin within a few months. Doctors just had to keep Mitchell alive until that happened. Rady neonatologist Jeanne Carroll says that “having his whole genome allowed us to know the starting point” for treatment. She and Mitchell’s team of physicians prescribed a series of blood transfusions, and the baby improved rapidly. In just under a month he was strong enough to go home.

For children like Mitchell who are born with a genetic disease, it used to take years to get a diagnosis, and by then it often was too late. Now, however, advances in the speed of genetic sequencing and steeply falling costs have made it possible to screen for hundreds or even thousands of childhood-onset genetic diseases. Within the past year or so a few dozen hospitals have started offering the ability to rapidly sequence a newborn’s genome to help diagnose a life-threatening condition soon after birth. Researchers are studying whether such sequencing should be offered to all newborns as part of standard health screening. And companies such as Sema4 and BabyGenes are now marketing 23andMe-style direct-to-consumer tests to parents simply seeking to know more about the health of their baby. Prenatal and newborn genetic sequencing is expected to grow to an $11.2-billion industry by 2027, up from a $4-billion market in 2018.

Proponents say that genetic testing of newborns can help diagnose a life-threatening childhood-onset disease in urgent cases and could dramatically increase the number of genetic conditions all babies are screened for at birth, enabling earlier diagnosis and treatment. It could also inform parents of conditions they could pass on to future children or of their own risk of adult-onset diseases. Genetic testing could detect hundreds or even thousands of diseases, an order of magnitude more than current heel-stick blood tests—which all babies born in the U.S. undergo at birth—or confirm results from such a test.

But others caution that genetic tests may do more harm than good. They could miss some diseases that heel-stick testing can detect and produce false positives for others, causing anxiety and leading to unnecessary follow-up testing. Sequencing children’s DNA also raises issues of consent and the prospect of genetic discrimination.

Regardless of these concerns, newborn genetic testing is already here, and it is likely to become only more common. But is the technology sophisticated enough to be truly useful for most babies? And are families—and society—ready for that information?

In the 1960s microbiologist Robert Guthrie developed a test for phenylketonuria (PKU), a genetic disorder that causes the amino acid phenylalanine to build up in the body. PKU is easily treated with a phenylalanine-restricted diet, but without intervention it can cause brain damage and mental disabilities. Within a few years other U.S. states required that Guthrie’s test be administered to newborns, and tests for other conditions were soon to follow. By the mid-1980s most states had mandatory screening programs. In 2002 the federal government asked the American College of Medical Genetics to develop guidelines for newborn screening, which culminated in the Recommended Universal Screening Panel, a set of 35 core conditions and 25 secondary ones that are treatable. Most states now test for a subset of these conditions.

There are roughly 14,000 known genetic diseases in humans, ranging from childhood-onset diseases such as PKU and congenital heart disease to adult-onset conditions such as Huntington’s disease and heritable forms of cancer. Some childhood diseases, such as PKU, are treatable if caught early. Heel-stick tests look for only a tiny fraction of these diseases, hence the appeal of genetic testing.

In the early 2010s researchers at the National Institute of Child Health and Human Development and the National Human Genome Research Institute launched a program, called NSIGHT (short for Newborn Sequencing in Genomic Medicine and Public Health), to explore the risks and benefits of DNA screening of newborns. Rady’s Kingsmore led one of four projects funded by NSIGHT, which explored the use of rapid, whole-genome sequencing in extremely sick newborns suspected of having a genetic disease.

Standard sequencing can take weeks, but using a rapid sequencing method and software that compared the genome with the patient’s disease characteristics, Kingsmore’s team could get a genetic diagnosis back in as little as a day or two. For these babies, hours or days can be the difference between life and death or severe disability. The first of two trials led by Kingsmore took place from 2014 to 2016 at Children’s Mercy Hospital in Kansas City. The second ran from 2017 to 2019 at Rady Children’s. Within the past year the group has started offering newborn sequencing at 23 hospitals around the country, and lawmakers from California have introduced federal legislation to cover the cost of sequencing critically ill babies through Medicaid. As of last November, Kingsmore and his colleagues had sequenced more than 1,100 babies with suspected genetic diseases. About one in three of them received a diagnosis that identified an illness, and one in four had their existing treatment changed as a result.

Mitchell Gorby was one of those sequenced at Rady (but not as part of NSIGHT). Carroll, the Rady neonatologist, says the information “helped us more confidently give him more transfusions and hold off on other testing.” It is possible Mitchell may have survived and outgrown his disorder without the test and diagnosis. But in other cases, sequencing has very likely saved lives. Moreover, sequencing probably significantly reduced the diagnostic odyssey such children have to take, Kingsmore says.

Extremely sick babies are not the only ones who could benefit from genetic testing. Another NSIGHT project investigated whether sequencing could also be used in clinical settings to screen newborns with no obvious signs of disease.

For this study, called the BabySeq Project, Robert Green of Brigham and Women’s Hospital, Alan Beggs of Harvard Medical School and their colleagues recruited families and randomly assigned half of them to have their babies’ genomes sequenced. They developed a list of about 1,500 genes that were highly associated with diseases that begin in childhood or adolescence, then returned information about a subset of those genes to the families. The goal was to do the most comprehensive testing possible—to see anything and everything that could be discovered about gene-based risks. Last January the group reported sequencing results from 159 newborns—mostly healthy babies but also some ill ones in the neonatal ICU. The scientists found that 9.4 percent of the healthy group were at risk of developing a childhood-onset disease that was not known from their medical or family history, and 88 percent were carriers for recessive diseases.

So was the testing worth it for parents? A mother named Natalie, who requested we use only her first name out of concern for her family’s privacy, has a son who was enrolled in BabySeq. Natalie, who is a physician and lives in Washington, D.C., admits she felt some nervousness about the testing. “Whenever you have the chance to learn about the health of your child, there’s an opportunity for anxiety,” she says. But overall, she and her husband were comfortable with the project. “Because they were looking at only genetic defects that affect childhood and only illnesses that had some preventive measures, we felt it could potentially be useful,” she says.

Fortunately, the results of tests on her son, Russell, did not turn up any childhood-onset genetic disorders. The exams did indicate that he may be a carrier for a recessive metabolic disorder called Gaucher disease, but the sequencing of this gene is particularly prone to error, so he will need follow-up testing to confirm. For other families, the benefits of sequencing were more clear-cut: one child had a disorder—missed by standard screening—that makes the body unable to recycle a vitamin called biotin; the condition can cause coma and death if left untreated, but it can easily be treated by supplementation.

Although BabySeq was initially focused only on childhood-onset disorders, one baby in the study was found to carry a variant of the BRCA2 gene, which is associated with a high risk of breast and other cancers, so the researchers asked parents for permission to inform them of the risk of adult-onset disorders if they chose. Natalie and her husband opted not to receive this information but said they would leave it up to Russell if he wanted to be tested when he was older. “We felt it should be our son’s decision,” Natalie says.

Because of its complexity and cost, BabySeq was never intended to be a feasible addition to standard newborn screening. “We have not tried to advocate for this in clinical practice,” Green of Brigham and Women’s says. But sequencing tests are no longer confined to clinical practice. Several companies now offer direct-to-consumer DNA tests for newborns. The firm Sema4 sells a test for $379 that it says screens for more than 190 genetic conditions that can occur before the age of 10 and that can be treated with medication, diet or other interventions. The company gives results to parents in a genetic-counseling session about four to six weeks after the test. Sema4’s CEO, Eric Schadt, says the test can detect disease-related genetic variants with 99 percent accuracy. Sema4 only reports results for diseases that have a greater than 80 percent penetrance—the proportion of people with a genetic variant who end up developing the disease. It also discloses information about the child’s sensitivity to certain drugs, although the U.S. Food and Drug Administration has recently been pressuring companies not to make such information available, because it says that it has not reviewed the tests and that they may not be backed up by clinical evidence.

Another company, BabyGenes, offers a test that scours 100 genes for more than 72 conditions. It is offered in the form of either a cheek swab or dried-blood spot test and retails for $349.

Schadt admits Sema4 doesn’t know whether the kind of testing it offers leads to an overall benefit for patients, although he says the company is doing studies to find out. There are reasons to wonder. The accuracy of these tests in detecting disease is still uncertain. In a third NSIGHT project, led by Jennifer Puck, Barbara Koenig and Pui-Yan Kwok of the University of California, San Francisco, researchers sequenced the DNA of dried spots of blood left over from newborn heel-stick tests (California has kept all its blood spots since the early 1980s). Although the sequencing did detect some genetic conditions that the standard newborn screening panel does not test for, it missed some of those that standard screening caught. And it flagged a lot of genetic variants of unknown significance, Puck says: “Newborn screening is very different from having a sick individual in front of you for whom you’re trying to arrive at a diagnosis.”

When combined with the standard screening, DNA testing did reduce the number of false positives, however. Puck thinks sequencing could be an add-on to standard screening when there’s an abnormal result, but she doesn’t think it should be used to screen all healthy babies. “We’re just not at the point where we can interpret the sequence with sufficient predictive value to say ‘yes’ or ‘no,’ this is a disease or not,” she says.

Another issue that concerns physicians and medical ethicists is the possibility that genetic testing will cause unnecessary anxiety for parents about diseases that may appear later in life or never show up at all. “When it comes to genetic information about your child, a lot of people aren’t in a position to well interpret what the results mean,” says Nita Farahany, a professor of law and philosophy at Duke University School of Law, who is an expert in genetics and bioethics. “If they’re told their child has a four times greater risk [of some condition], but the population risk is 1 percent, how do they treat their children?” There is already a shortage of genetic counselors in the U.S., so there would not be enough people to help parents understand their child’s genetic results.

Then there’s the issue of privacy. If the child’s genetic information is stored on file, who has access to it? If the information becomes public, it could lead to discrimination by employers or insurance companies. The Genetic Information Nondiscrimination Act (GINA), passed in 2008, prohibits such discrimination. But GINA does not apply to employers with fewer than 15 employees and does not cover insurance for long-term care, life or disability. It also does not apply to people employed and insured by the military’s Tricare system, such as Rylan Gorby. When his son’s genome was sequenced, researchers also obtained permission to sequence Rylan’s genome, to determine if he was a carrier for the rare hemoglobin condition. Because it manifests itself only in childhood, Gorby decided taking the test was worth the risk of possible discrimination.

Cost is another consideration. Clinical sequencing is still about $500 to $800, and interpretation can be upward of $1,000, according to Brigham and Women’s Green. For families who can’t afford health insurance, this is out of reach. Some experts have also raised concerns that genetic testing could lead to a lot of follow-up testing with specialists, which could overburden an already resource-strapped health care system. If sequencing turns out to save money in the long run, insurance companies may cover it, but there’s no guarantee.

Yet another problem is that the majority of the sequencing to date has been done in babies whose families are well-off and white, raising concerns that this could become the province of only the privileged. And the racial homogeneity could skew the results: diseases more prevalent in Caucasian individuals could be overrepresented in test panels, whereas illnesses more common in racial minorities may be underrepresented. (New medical data projects intend to address this disparity [see “All of Us”].)

The U.C.S.F. NSIGHT project included a working group that investigated some of these ethical and policy issues, which culminated in a 2018 report by the Hastings Center, a bioethics nonprofit in Garrison, N.Y. The report concluded that newborn sequencing has many benefits in helping diagnose sick babies and could expand the number of conditions that meet the stringent newborn screening criteria. But using genome sequencing as a replacement for newborn screening is “at best premature,” the authors say, and direct-to-consumer sequencing should not be used for diagnosis or screening purposes.

Barbara Koenig, a professor of medical anthropology and bioethics at U.C.S.F. and one of the report’s co-authors, underscores the fact that sequencing, while promising, is not yet mature enough to be routinely used to screen healthy children. “This is not a technology that’s ready for prime time for use in healthy infants,” Koenig says.

Despite these concerns, the era of newborn sequencing is now upon us, and the practice will likely become more widespread as costs come down and the results become more accurate and useful. In the meantime, the risks and benefits of sequencing must be weighed on an individual basis. Extremely sick newborns are a completely different case from apparently healthy children of worried parents susceptible to marketing from genetic-testing firms.

For Mitchell Gorby, sequencing was certainly worth it. Two months after leaving the hospital, he is doing fine and has doubled his weight. His parents are settling into their new routine, somewhat sleep-deprived, but happy to be home with their healthy baby boy.

#science #medicine #biotech #genetics #health #medblr #academia

43 notes · View notes

shital1998 · 2 years ago

Text

Genetic Testing Market – Global Opportunity Analysis and Industry Forecast (2022-2029)

Meticulous Research®—a leading global market research company, published a research report titled, ‘Genetic Testing Market By Product (Consumables, Reagents, Instruments, Services), Test Type (Diagnostic, Prenatal, Carrier, Newborn, Preimplantation), Method (Molecular, Chromosomal), End User (Hospitals, Diagnostic Laboratories) - Global Forecast to 2029.’

According to this latest publication from Meticulous Research®, the genetic testing market is expected to grow at a CAGR of 11.6% from 2022 to reach $43.3 billion by 2029. The growth of this market is attributed to factors such as favorable government initiatives for promoting genetic testing, increasing prevalence of genetic disorders, increased need for early disease detection & prevention, increasing applications of genetic testing in oncology, and decreasing cost of sequencing procedures. In addition, the growing scenario of genetic direct-to-consumer genetic testing and the emerging field of genetic counseling is expected to provide significant growth opportunities for this market.

However, factors such as the high cost of genetic testing and the social and ethical implications of genetic testing are restraining the growth of this market to a notable extent. In addition, factors such as low chances of positive, actionable mutations and genetic data privacy & security concerns are the major challenges to the growth of this market.

Genetic Testing Market: Future Outlook

The genetic testing market is segmented based on product, test type, method, end user, and geography. The study also evaluates industry competitors and analyzes the market at the country level.

Download Research Sample https://www.meticulousresearch.com/download-sample-report/cp_id=5370

Scope of the Report:

Genetic Testing Market, by Product & Service

· Consumables & Reagents

· Instruments

· Services

Genetic Testing Market, by Test Type

· Diagnostic Testing

· Prenatal Testing

· Carrier Testing

· Newborn Screening

· Preimplantation Testing

· Other Test Types (Other test types include forensic testing, microorganism genomics, and posthumous (testing of post-mortem tissues etc.)

Genetic Testing Market, by Method

· Molecular Tests

· Chromosomal Tests

· Biochemical Tests

Genetic Testing Market, by End User

· Hospitals & Clinics

· Diagnostic Laboratories

· Academic & Research Institutes

· Others End Users (Other end users include contract research organizations, forensic laboratories, pharma & biotech companies, government laboratories, etc.)

Genetic Testing Market, by Geography

· North America

o U.S.

o Canada

· Europe

o Germany

o France

o U.K.

o Italy

o Spain

o Rest of Europe (RoE)

· Asia-Pacific

o China

o Japan

o India

o Rest of APAC (RoAPAC)

· Latin America

· Middle East & Africa

Speak with Our Analyst: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5370

Based on product, in 2022, the consumables & reagents segment is estimated to account for the largest share of this market. The large share of this segment is attributed to factors such as the recurrent use of reagents & consumables, availability of a wide range of genetic tests, recent product launches, and increased awareness about the advantages of genetic testing.

Based on test type, in 2022, the diagnostic testing segment is estimated to account for the largest share of this market. The large share of this segment is attributed to factors such as the high prevalence of chronic diseases such as cancer, technological advancements in genomic-based diagnostic testing, and the demand for early disease diagnosis.

Based on method, in 2022, the molecular segment is estimated to account for the largest share of this market. The large share of this segment is attributed to the ability to detect the mutation at single nucleotide resolution with cheaper, faster, and with the utmost accuracy by using whole genome sequencing (WGS) and whole exome sequencing (WES) technology.

In 2022, based on end user, the hospitals & clinics segment is estimated to account for the largest share of the market. The large share of this segment is attributed to the high volume of genetic tests performed in hospitals & clinics and the high demand for early disease diagnosis and treatment.

This research report analyzes major geographies and provides a comprehensive analysis of North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, and RoE), Asia-Pacific (Japan, China, India, and RoAPAC), Latin America, and the Middle East & Africa.

In 2022, North America is estimated to account for the largest share of the genetic testing market, followed by Europe and Asia-Pacific. North America’s large market share is attributed to the factors such as high healthcare expenditure, favorable reimbursement scenario, high awareness among patients about genetic testing, and increased support and investments to enhance genome sequencing infrastructure in the region.

Access full Report Description, TOC, Table of Figure, Chart, etc: https://www.meticulousresearch.com/product/genetic-testing-market-5370

Key Players

The key players operating in the genetic testing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Quest Diagnostics Incorporated (U.S.), Eurofins Scientific SE (Luxembourg), 23andMe, Inc. (U.S.), Foundation Medicine, Inc. (U.S.) (Subsidiary of Roche Holding AG), Rosetta Genomics Ltd. (U.S.), OPKO Health Inc. (U.S.), Natera, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Myriad Genetics, Inc. (U.S.), Laboratory Corporation of America Holdings (U.S.) and Invitae Corporation (U.S.).

Key questions answered in the report-

· Which are the high-growth market segments in terms of product, test type, method, end user, and region/country?

· What was the historical market size for genetic testing across the globe?

· What are the market forecasts and estimates for the period 2022–2029?

· What are the major drivers, restraints, opportunities, and challenges in the global genetic testing market?

· Who are the major players in the genetic testing market?

· How is the competitive landscape, and who are the market leaders in the global genetic testing market?

· What are the recent developments in the global genetic testing market?

· What are the different strategies adopted by the major players in the global genetic testing market?

· What are the geographical trends and high-growth regions/countries?

Meticulous Research

Email-

[email protected]

Contact Sales- +1-646-781-8004

Connect with us on LinkedIn-

https://www.linkedin.com/company/meticulous-research

#Genetic Testing Market #Genetic Testing #health #healthcare #medical devices #medical #diagnostics #newborn screening #molecular tests #biochemical #business #industry #market research

1 note · View note

rohit890 · 2 years ago

Text

Newborn Screening Market Key Players, Share, Trends, Sales, Segmentation And Forecast To 2031

Market Overview

The global newborn screening market was valued at USD 1.7 billion in 2021 and it is anticipated to grow up to USD 3.7 billion by 2031, at a CAGR of 8.0% during the forecast period.

Newborn screening identifies conditions that can affect a childs long-term health or survival. This screening technology includes a series of tests essential for timely detection, early diagnosis, and health management to prevent overall disability and avert death of a child. These tests are performed shortly after the baby is born, and detect genetic, developmental, and metabolic disorders in newborn babies. Newborn screening is done by using a few drops of blood from the newborn’s heel, for certain genetic, endocrine, and metabolic disorders, and are tested for hearing loss and critical congenital heart defects (CCHDs) prior to discharge from a hospital or birthing center.

View Detailed Report Description: https://www.globalinsightservices.com/reports/newborn-screening-market/

Market Dynamics

The prevalence of newborn diseases has risen in recent years, prompting providers to raise awareness and support the demand for advanced screening instruments. Hearing, metabolic, and hormonal disorders and critical congenital heart disease are the major newborn disorders; most are treatable if diagnosed early. For instance, according to the US CDC, during 2015–2017, the prevalence of newborn disorders was 34 per 10,000 live births in the US. Approximately 12,900 infants are expected to be identified each year with a disorder. Moreover, according to the same source, the most prevalent disorders are hearing loss (16.5 per 10,000), congenital hypothyroidism (6.0 per 10,000), sickle-cell disease (4.9 per 10,000), and cystic fibrosis (1.8 per 10,000). Such scenario will propel the industry growth.

Several ethical concerns related to prenatal and new-born testing may hamper the market progression. Prenatal and new-born genetic testing raises complex ethical issues further limiting the development of clinical services and implementation of public policy related to access and funding. The use of screening in selective abortion has raised several concerns. The rising occurrence of false results in prenatal and new-born genetic testing might decrease the adoption of genetic testing. For instance, around 5% of women are tested false-positive during prenatal testing for Down syndrome.

Get Free Sample Copy of This Report: https://www.globalinsightservices.com/request-sample/GIS10337

The key players in the market are PerkinElmer (US), Demant A/S (Denmark), Natus Medical (US), Bio-Rad Laboratories (US), Danaher Corporation (US), Medtronic (Ireland), Chromsystems Instruments & Chemicals GmbH (Germany), Trivitron Healthcare (India), Baebies (US) and Recipe Chemicals+Instruments (Germany), among others.

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

Global Insight Services LLC

16192, Coastal Highway, Lewes DE 19958

E-mail: [email protected]

Phone: +1–833–761–1700

0 notes

the-rachana · 2 years ago

Text

Digital Genome Market Is Thriving Worldwide – BioMérieux, Inscripta Inc., Agilent Technologies Inc., F. Hoffmann-La Roche Ltd.

The scientific community has tried to address genetic susceptibility and severity to SARS-CoV-2 infection by combining research efforts using existing genetic databases. Multiomic-based approaches and genome-wide association studies (GWAS) have been employed to uncover biological networks and common variants underlying host-pathogen interactions. Similarly, data derived from genomes, such as polygenic risk scores (PRS), ABO blood groups, and HLA haplotypes, can be potentially used to decipher COVID-19 complications, resistance, and susceptibility.

The global Digital Genome market reached ~US$ 12.1 billion in 2021. The market is expected to witness a CAGR of 10% from 2022 to 2030.

Prenatal genetic screening programs are likely to grow at a significant pace. This is because these programs help expectant mothers identify chromosomal anomalies in their offspring. Moreover, it is anticipated that in the next 10 years, every newborn’s genome would be sequenced and stored in the electronic medical record. Gauging the future market potential of genomics in newborn screening programs, emerging companies like Counsyl and Natera have launched various genetic tests to maintain their competitive edge in the market.

Get a Sample PDF of the Report - https://growthplusreports.com/inquiry/request-sample/digital-genome-market/7910

Key Players

· BioMérieux

· GenMark Diagnostics, Inc.

· Illumina, Inc.

· Thermo Fisher Scientific

· NanoString Technologies, Inc.

· Inscripta Inc.

· GE Healthcare Genomic Health, Inc.

· Pacific Bioscience, PerkinElmer Inc.

· Qiagen Quest Diagnostics

· Agilent Technologies Inc.

· Becton, Dickinson and Company

· F. Hoffmann-La Roche Ltd.

· Regeneron Pharmaceuticals, Inc.

By Product Type

· Sequence & Analysers Instruments

· DNA/RNA Analysis kits

· Sequencing & Analysis Software

· Sample Preparation Instrument

By Application

· Microbiology

· Reproductive & Genetic

· Transplant & Agriculture

· Forensics

· Research & Development

Key Reasons to Purchase:

(1) To gain insightful analyses of the market and have a comprehensive understanding of the global market and its commercial landscape.

(2) Assess the production processes, major issues, and solutions to mitigate the development risk.

(3) To understand the most affecting driving and restraining forces in the Digital Genome Market and its impact in the global market.

(4) Learn about the market strategies that are being adopted by leading respective organizations.

(5) To understand the outlook and prospects for the market.

Key Questions Answered in the Report Include:

(1) This report gives all the information about the industry analysis, revenue, and overview, of this market.

(2) What will be the rate of increase in market size and growth rate by the end of the forecast period?

(3) What are the major global Digital Genome Market trends influencing the development of the market?

(4) What are the vital results of SWOT analysis of the major players operating in the Digital Genome Market?

(5) What are the potential growth opportunities and threats faced by Major competitors in the market?

TOC of Digital Genome Market

1 Scope of the Report

1.1 Market Ecosystem

1.2 Geographic Scope

1.3 Timeline Under Consideration

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Digital Genome Market Executive Summary

2.1 World Market Overview

2.1.1 Global Market Size 2022-2030

2.1.2 Market Size CAGR by Region 2020 VS 2028

2.2 Digital Genome Market Segment by Type

2.2.1 Type 1

2.2.2 Type 2

Browse the full report now: https://growthplusreports.com/report/digital-genome-market/7910

About us

Growth+Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth+ portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis, and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.

0 notes

meditech-insights · 2 years ago

Text

Non-Invasive Prenatal Testing Market is expected to grow at a CAGR of 16% to reach ~$9 billion by 2026

Non-invasive prenatal testing (NIPT), is a method of determining the risk of whether the fetus of the mother will be born with specific genetic disorders. NIPT is a safe and extremely effective way of screening for conditions such as Down syndrome, Edwards syndrome, Patau syndrome, monosomy X, and Turner syndrome.

Currently, massive parallel sequencing (MPS) technology and the single-nucleotide polymorphism (SNP) based method are the two types of NIPT methods that are commercially accessible.

The Global Non-Invasive Prenatal Testing Market is expected to grow at a rate of 16% to reach ~$9 billion by 2026. Rising acceptance of cell-free DNA screening, advantageous reimbursement policies for average and low-risk pregnancies, high risk of chromosomal abnormalities with increasing maternal age, and increasing prevalence of genetic and congenital disorders are some of the main factors driving the global non-invasive prenatal testing market.

Change towards Cell-Free DNA screening

The Discovery of cell-free DNA (cfDNA)-based NIPT has created a rapid shift in the paradigm of aneuploidy screening during pregnancy. It is a simple blood test that may be done while pregnant. Clinical validation research shows that NIPT is more accurate than combined first-trimester screening (CFTS), with very high sensitivity (99.3%) and specificity (99.9%) for trisomy 21(Down syndrome). NIPT is also safer than other invasive diagnostic techniques like chorionic villus sampling and amniocentesis, which involves a risk of miscarriage (0.1–0.2%).

Arrival of Advanced Technologies for NIPT Products

The advent of next-generation sequencing technology has enabled the sequencing of fetal DNA fragments that can be assembled into a full genetic map, allowing the fetal genome to be scanned prenatally and non-invasively. Advances in molecular technologies and the discovery of cell-free fetal DNA in maternal plasma have also led to novel screening methods for fetal chromosomal aneuploidies.

The market now offers a variety of NIPT tests including Panorama, Vistara, MaterniT GENOME, Harmony Test, among others which help in the screening of chromosomal abnormalities developing in the fetus.

Additionally, several developments have been made to impact the quality of care for expectant mothers such as:

In January 2022, QIAGEN entered into collaborations with Atila BioSystems to provide non-invasive prenatal testing (NIPT) solutions to QIAGEN’s dPCR franchise.

In June 2021, Illumina and Next-generation Genomic Thailand announced the launch of next-generation sequencing (NGS)-based VeriSeq NIPT Solution v2 in the country which helps to detect anomalies missed by targeted assays.

“Prenatal care is a dynamic and continuously evolving field. Development in new molecular technologies and the discovery of cell-free fetal DNA are fueling groundbreaking advancements to improve care for mother and child and to offer parents reproductive options.” - Senior Director, Head of Research & Product Development, Sequencing & Array-based Company, United States

Explore Premium Report on Non-Invasive Prenatal Testing Market @ https://meditechinsights.com/non-invasive-prenatal-testing-market/

Key Challenges/ Constraints: Non-Invasive Prenatal Testing Market

Some of the key challenges limiting the growth of the non-invasive prenatal testing market are stringent government regulations, and limitations of NIPT such as despite its high accuracy, it is still considered a screening test.

North America: The Largest Non-Invasive Prenatal Testing Market

North America is the major market for NIPT with >45% revenue share, followed by Europe. Some of the main reasons propelling the North America market include the rising prevalence of genetic disorders in newborns associated with increasing maternal age, wider adoption, and the presence of top players working on fetal and neonatal care in this region.

The market in Europe is predicted to expand considerably over the forecast period due to the adoption of the latest technology, new product launches, and a strong reimbursement framework for these tests in the region. The Asia Pacific region is anticipated to witness the highest CAGR in the coming years.

Competitive Landscape Analysis of Non-Invasive Prenatal Testing Market

Some of the prominent players operating in the global non-invasive prenatal testing market are Agilent Technologies, BGI Genomics, Cradle Genomics, Berry Genomics, Sequenom, Roche (Ariosa Diagnostics), among others.

For More Detailed Insights, Contact Us @ https://meditechinsights.com/contact-us/

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

Contact:

Ruta Halde

Associate, Medi-Tech Insights

+32 498 86 80 79

[email protected]

#Healthcare #Non-Invasive-Prenatal-Testing-Market

0 notes

pranalipawarshinde · 3 years ago

Text

Genetic Testing Services Market Size, Growth, Trends and Forecast Report 2019-2027

Genetic Testing Services Market:Overview

Transparency Market Research (TMR) has published a new report titled, ‘Genetic Testing Services Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.According to the report, the global Genetic Testing Services market was valued at US$ 41.2 Bn in 2018 and is projected to expand at a CAGR of 7.3% from 2019 to 2027.

Overview

Genetic Testing is a medical test also known as DNA testing which determine changes in the chromosomes, genes, and proteins. This testing can suspect or rule out the suspected genetic conditions which determine any genetic disorder or diseases in the patients.

Various genetic testing available in the market are molecular genetic tests, chromosome genetic tests, and biochemical genetic tests. These tests study the single genes, whole chromosomes, and identify the abnormalities or activity level of the proteins.

Genetic testing would help in diagnosing diseases, severity of the disease, diagnosis or identifying the changes in the genes, inherited risk of developing the diseases, and also enables the patient and physicians for establishing the optimum treatment.

Report Overview: https://www.transparencymarketresearch.com/genetic-testing-services-market.html

New Born Screening Segment to Dominate Global Genetic Testing Services Market

In terms of test type, the global genetic testing services market has been segmented into prenatal testing, newborn screening, predictive & presymptomatic testing, pharmacogenomic testing, and others.

New Born Screening segment likely to grow at highest growth care during forecast period. Rise in neonatal diseases, and increasing pediatric patients suffering from diseases are propelling factor for the segment growth in coming years.

Predictive and Presymptomatic Testing is another segment likely to held major market share in genetic testing services market. Genetic mutation leading to the development of various chronic diseases boosting the need of genetic testing services market during forecast period.

Oncology Segment Hold a Major Share of Global Genetic Testing Services Market

In terms of application, the global genetic testing services market has been classified into oncology, infectious diseases, autoimmune diseases and others. Oncology segment dominated the market in 2018 and it would continue its dominance during the forecast period.

Attributable factors driving the segment growth ascribed to the rising incidences of breast cancer, colorectal cancer, lung cancer and other types across globe. Moreover, early diagnosis of the cancer through genetic testing is another driving factor for the segment growth in coming years. Predictive test of breast cancer is another propelling factor for the segment growth during forecast period.

Request A Sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=10235

Hospitals based laboratories Segment to Dominate Global Genetic Testing Services Market

Based on service providers, the global genetic testing services market has been segmented into hospitals based laboratories, diagnostic laboratories, speciality clinics, and others. Hospitals based laboratories segment accounted for major share of the market. Rising incidence of diseases, increasing hospital stays, and growing geriatric population are few major factors expected to boost the segment during the forecast period. Moreover, long-term care of patients suffering from chronic diseases required expertise and standard diagnosis process likely to accelerate the hospital based laboratories segment during forecast period.

Speciality clinics to grow at rapid growth care during forecast period, owing to increasing investments and extensive R&D activities and wide outsourcing of a few specialty tests are factors fueling the speciality clinics segment.

North America to Dominate Global Genetic Testing Services Market

In terms of region, the global genetic testing services market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global genetic testing services market in 2018, followed by Europe.

Request for covid19 Impact Analysis: https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=10235

North America accounted for major share of the global genetic testing services market in 2018. Technological advancements, presence of key players, launching of novel products, demand of diagnostics for cancer detection, rising prevalence and incidences of autoimmune, infectious diseases in the region are attributable factors for the market growth of the region.

The Genetic Testing Services market in Asia Pacific is anticipated to expand at a highest growth rate from 2019 to 2027. Increasing patient burden suffering from chronic diseases, and recent merger & acquisitions amongst key players offering genetic testing and services are estimated to propel the market in the Asia-Pacific region during forecast period.

Competitive Landscape

The global genetic testing services market is consolidated in terms of number of players. Key players in the global Genetic Testing Services market include Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Genomic Health, Inc., NeoGenomics Laboratories, Inc, Eurofins Scientific, Ambry Genetics, Illumina, Inc, 23andMe, Inc., Exact Sciences, Natera, Invitae, Veracyte, and other prominent players.

More Trending Reports by Transparency Market Research:

Transplant Drug Monitoring Assay Market: https://www.transparencymarketresearch.com/transplant-drug-monitoring-assay-market.html

PRP and PRF in Cosmetics Market: https://www.transparencymarketresearch.com/prp-and-prf-in-cosmetics-market.html

Fetal Bovine Serum Market: https://www.transparencymarketresearch.com/fetal-bovine-serum-market.html

Cell Culture Market: https://www.transparencymarketresearch.com/cell-culture-market.html

Mice Model Market: https://www.transparencymarketresearch.com/mice-model-market.html

Molecular Diagnostics Market: https://www.transparencymarketresearch.com/molecular-diagnostics-industry.html

Human Microbiome Market: https://www.transparencymarketresearch.com/human-microbiome-market.html

Contraceptives Market: https://www.transparencymarketresearch.com/contraceptives-market.html

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit Bhisey Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Website: https://www.transparencymarketresearch.com Blog: https://tmrblog.com Email: [email protected]

0 notes

shreyas-inkwood · 3 years ago

Text

Genetic Testing Market Growth & Trends | Analysis by 2030

Genetic testing is one of the rapidly evolving segments in the healthcare sector. It is estimated that the global genetic testing market will evolve at 10.25% of the CAGR between 2022 and 2030. The increasing incidence of genetic diseases and the rising applications build the groundwork for the market’s opportunistic progression.

Genetic testing helps identify changes in proteins, chromosomes, or genes. The results can rule out or confirm a suspected genetic condition and determine the chances of passing or developing a genetic disorder.

The top trend-setting factors in the market are the rise in the aging population and technological advancements. As per the United Nations’ World Population Prospects 2020 Highlights, more than 1.5 billion will be aged over 65 by 2050. The aging population is vulnerable to chronic diseases, thereby raising the demand for preventive diagnostics, especially genetic testing. Further, the growing cases of inherited diseases like hemophilia, cystic fibrosis, and sickle cell anemia are pushing the need for genetic testing.

Genetic Testing Market by Segmentation | Trends 2022

The global genetic market report scope includes the segmentation analysis of disease, application, technology, and type. The government initiatives in terms of genetic testing awareness, the rising disposable income, and technological advancements facilitate the growth of key segments like type and disease. For instance, genetic testing is increasingly being used in pharmacogenomics, also called drug-gene testing. This is also attributed to the genetic testing techniques advancements.

The cancer segment is expected to have the largest revenue share in the global genetic testing market by disease.

Cancer is the second-leading cause of death, with almost 70% of deaths occurring in low-and-middle-income countries. Genetic testing aids in estimating the chances of developing cancer by assessing the specific changes in genes, chromosomes, and proteins. This leads to increased surviving probability, cost-effective treatment, and minimal morbidity.

The increasing awareness about personalized medicine and preventive diagnosis, and the growing cancer burden, contribute to the segment growth. According to the International Agency for Research on Cancer (IARC), the new cancer incidence is predicted to reach 30.2 million by 2040.

Furthermore, the growing technological advancements and product launches boost the cancer segment’s growth. For instance, Roche launched the Cobas PIK3CA Mutation Test in December 2020 for detecting PIK3CA mutations in advanced or metastatic breast cancer patients.

Moreover, the rising popularity of direct-to-consumer channels, the growing adoption of self-testing kits, increased consumer expenditure on healthcare, and easy access to genetic testing services boost growth opportunities in the type segment.

The prenatal & newborn testing segment is evaluated to be the fastest-growing test type.

This is accredited to surging demand to identify health complications in newborn or prenatal babies, particularly in developed countries. Also, prenatal screening helps identify several health conditions like Down syndrome, Edward syndrome, and patau syndrome. Further, as per the Centers for Disease Control and Prevention, the perinatal mortality was stable, with stillbirth affecting almost 1% of all pregnancies in the US in 2012.

In addition, extensive research associated with genomics and proteomics and heavy investments in research activities has resulted in substantial technological advancements.

Asia-Pacific is expected to project more growth opportunities given the increased government initiatives, the rising research activities, large population, awareness of early screening of genetic disorders, growing medical tourism, and increasing demand for quality healthcare. Whereas North America is estimated to fare more in terms of revenue share due to the presence of key players like 23andMe, Myriad Genetics Inc, PerkinElmer Inc, Illumina Inc, etc., a strong base of healthcare facilities, and a surging pregnancy rate.

Future Potential

Some aspects of most diseases are influenced by changes in the patient’s genome. In this regard, there is immense potential for genetic testing in promising applications like tumor molecular profiling like liquid biopsies to select cancer treatment, sequencing for rare diseases, and non-invasive prenatal diagnostics. Additionally, the increasing acceptance and accessibility of non-targeted sequencing among consumers and patients are evaluated to offer growth opportunities for the global genetic testing market.

#Genetic Testing Market #genetic testing #healthcare #inkwood research #market research report #market research reports #market research

0 notes

tmr123123 · 3 years ago

Text

Non-invasive Prenatal Testing (NIPT) Market 2021 Recent Developments, Segmented Data and Business Operation Data Analysis by 2030

Trends Market Research has introduced the addition of a new report entitled Global Non-invasive Prenatal Testing (NIPT) Market Growth 2021-2027 includes the regional and global market facts, which is estimated to acquire moneymaking valuation over the forecast length from 2021 to 2027. The file explains the market definition, classifications, applications, engagements, and global Radon Fans enterprise developments are.

The report provides an understanding of the industry competitors; the assessment consists of the market shares of the competitors, as well as the market developments, demands, drivers, opportunities, demanding situations, product analysis. The sales channel, growth potential, potentially disruptive trends, industry product innovations, and the value/volume of size, market segments. Current market developments and dynamics helps in mapping the track of the global Non-invasive Prenatal Testing (NIPT) Market.

Request for Sample with Complete TOC and Figures & Graphs @ https://www.trendsmarketresearch.com/report/sample/9844

According to TMR Research analysis, North America accounted for the largest share in the global non-invasive prenatal testing market in 2018 and will retain a high position during the forecast period. According to WHO estimation, the prevalence of Down syndrome is between 1 in 1,000 and 1 in 1,100 live births worldwide. The incidence of Down syndrome is 1 in 212 with the women age between 35 and 39 and the risk significantly increases with maternal age, i.e., above 45, the incidence rate is 1 in 33 newborns. But the risk rate is very low in younger women in the age group of 24–25 years with incidence rate reduced to 1 in 1429. The risk of aneuploidy also increases with maternal age with an incidence rate of 1 in 192 for women in the age group of 35 years and 1 in 66 in the age group up of 40. Favorable reimbursement policies, availability of advanced technologies, presence of prominent vendors, and an increase in the prevalence of genetic disorders will increase the adoption and demand for tests in this region. Asia Pacific is expected to grow at a high CAGR during the forecast period, owing to factors such as increasing awareness of early disease diagnosis, increasing healthcare expenditure, and presence of huge population base.

The report then focuses on the countries and regions of the globe, which presents the regional popularity of the market, including extent and value, market size, and price structure. Leading players of the global Non-invasive Prenatal Testing (NIPT) Market are investigated, organizations, consolidations or acquisitions, and markets served.

Non-invasive Prenatal Testing Market by Application:

Trisomy

Microdeletion Syndrome

Other NIPT Applications

The report additionally gives the global significant driving industry players of the market, for example, value, enterprise profiles, revenue, determination, creation, and contact data. The document suggests a portrayal of the geographical quantity of the global Non-invasive Prenatal Testing (NIPT) Market.

The countries covered in the market report are:

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Direct Purchase this Market Research Report Now @ https://www.trendsmarketresearch.com/checkout/9844/Single

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The research report has used the numbers and figures in a comprehensive way with the assist of graphical and pictorial representation, which represents more clarity at the global Non-invasive Prenatal Testing (NIPT) Market. The data factors such as the flow patterns, openings, drivers, restrictions, and information are accumulated through authentic sources for future plans for the industry.

Significance of the Report Which Makes It worth Buying:

A broad and precise understanding of the global Radon Fans industry is offered in the segmented form based on product types, applications, and regions

Understand the industry delivery chain with a deep dive on the value augmentation.

Understand the specific dynamics influencing the market – key using factors, challenges, and hidden opportunities.

Get Discount On The Purchase Of This Report @ https://www.trendsmarketresearch.com/report/discount/9844

0 notes